Insulet (NASDAQ:PODD) Trading 4.4% Higher After Insider Buying Activity

Shares of Insulet Corporation (NASDAQ:PODD) were up 4.4% during mid-day trading on Friday following insider buying activity. The stock traded as high as $154.49 and last traded at $152.8990. Approximately 343,377 shares changed hands during trading, a decline of 71% from the average daily volume of 1,171,243 shares. The stock had previously closed at $146.41.

Specifically, Director Timothy C. Stonesifer bought 2,790 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Analyst Ratings Changes

Several equities analysts recently issued reports on PODD shares. Wells Fargo & Company cut their target price on Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Leerink Partners dropped their price target on Insulet from $360.00 to $247.00 in a research note on Thursday, May 7th. Benchmark reissued a “buy” rating on shares of Insulet in a report on Wednesday, May 27th. Wall Street Zen upgraded Insulet from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings lowered Insulet from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 15th. Twenty-one research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $252.04.

Insulet Stock Up 4.5%

The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The business’s 50 day moving average price is $176.99 and its 200 day moving average price is $239.50. The firm has a market cap of $10.60 billion, a PE ratio of 35.48, a PEG ratio of 1.13 and a beta of 1.13.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping the consensus estimate of $1.19 by $0.23. The company had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.Insulet’s quarterly revenue was up 33.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities research analysts expect that Insulet Corporation will post 6.44 earnings per share for the current year.

Institutional Trading of Insulet

A number of hedge funds and other institutional investors have recently modified their holdings of PODD. Nordea Investment Management AB increased its stake in Insulet by 35.0% during the 4th quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock worth $157,128,000 after buying an additional 142,922 shares during the period. ING Groep NV grew its stake in shares of Insulet by 88.5% in the third quarter. ING Groep NV now owns 17,300 shares of the medical instruments supplier’s stock worth $5,341,000 after acquiring an additional 8,123 shares in the last quarter. Jain Global LLC grew its stake in shares of Insulet by 148.2% in the third quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier’s stock worth $32,945,000 after acquiring an additional 63,719 shares in the last quarter. Fisher Asset Management LLC increased its position in shares of Insulet by 38.1% during the third quarter. Fisher Asset Management LLC now owns 46,273 shares of the medical instruments supplier’s stock worth $14,286,000 after acquiring an additional 12,754 shares during the period. Finally, Mitsubishi UFJ Trust & Banking Corp increased its position in shares of Insulet by 26.5% during the fourth quarter. Mitsubishi UFJ Trust & Banking Corp now owns 43,921 shares of the medical instruments supplier’s stock worth $12,484,000 after acquiring an additional 9,206 shares during the period.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.